Global Pain Management Devices And Therapies Market

The anesthesia and respiratory devices market consists of sales of anesthesia and respiratory devices and related services by entities that manufacture anesthesia and respiratory devices used in the diagnosis and treatment of respiratory diseases such as asthma, cystic fibrosis, and acute respiratory distress syndrome.

The microbiology diagnostics devices and equipment market consists of sales of microbiology diagnostics devices and equipment and related services. Microbiology diagnostics devices and equipment are used to diagnose infectious diseases by examining pathogens. These instruments include incubators, autoclave sterilizers, anaerobic culture systems, blood culture systems, gram strainers, microscopes, mass spectrometers, molecular diagnostic instruments, reagents pathogen specific kits and general reagents. The market covered in the microbiology diagnostics devices and equipment market report is segmented by type into laboratory instruments, microbiology analysers; by end user into hospitals, diagnostic centres, customer lab service providers, academic institutes, research institutes; by laboratory instruments into incubators, gram stainers, bacterial colony counters, petri dish fillers, automated culture systems; by micro-biology analyzers into microbiology diagnostics instruments, microscopes; by reagents into pathogen-specific kits, general reagents. The global microbiology diagnostic devices and equipment market is expected to grow from $3.65 billion in 2020 to $4.36 billion in 2021 at a compound annual growth rate (CAGR) of 19.5%. The high growth is mainly due to the outbreak of COVID-19 that increased demand for the market. The microbiology diagnostics devices and equipment market is expected to reach $5.79 billion in 2025 at a CAGR of 7.3%. Increasing funding of public and private investments in the medical devices is driving the growth of microbiology diagnostic devices market. Increasing Investments indicates rising confidence of various private and public players on microbiology diagnostic devices thereby indicating a progressive increase and stimulating growth. For instance, India introduced ¥544 billion (~$4.90 billion) of medical devices in 2019 & transported ¥178 billion (~$1.60 billion) of medical devices with a market size at retail & institutional sales level of above ¥1500 billion (~$13.52 billion). It has the potential for above ¥ 1000 billion (~$9.02 billion) investment in medical devices over the next 5 years. The increasing investments on digital health technologies, artificial intelligence and non-invasive monitoring capability, delivery of gene therapy and regenerative medicines technologies, customized 3D printing of medical devices are expected to drive the microbiology diagnostic devices market. Unfavourable regulatory scenarios is one of the major restraints in the microbiology diagnosis devices market. In the US, section 510(k) of the Food, Drug and Cosmetic Act states that every device manufacturer must register with FDA and notify their intent to market a medical device at least 90 days in advance. These pre-market notifications are considered to be lengthy, rigorous and time-consuming processes for the approval of medical devices. If in case the submission fails due to some uncertainty, the company has to reperform all the tests and resubmit the premarket approval application. For instance, a 'Verticle Autoclave', a microbiology diagnostic device, complies with the strict international directives and standards such as capacity of 80-120 litre autoclave chamber volume, low sensitivity loads, restrictions on temperature calibration and a certificate from ISO17025 accreditation lab for temperature, pressure gauges & timer. Next Generation Sequencing (NGS) technologies are increasing their prevalence in the microbiology diagnostic devices market due to its cost effectiveness, sensitivity to detect low-frequency variants and comprehensive genomic coverage. Next Generation Sequencing (NGS) or high throughput sequencing or Massively Parallel Sequencing (MPS) is a method of sequencing genomes with an ability to sequence hundreds to thousands of genes or gene regions and capability to detect novel resistance genes (ARG) in bacteria. BioMérieux partnered with Illumina to develop bioMérieux EpiSe, a NGS service which will facilitate epidemiological monitoring of bacterial infections and monitor outbreaks in hospitals. Some of the modern next generation sequencing technologies that help to sequence DNA and RNA include Illumina (Solexa) sequencing, Roche 454 sequencing, Ion torrent Proton / PGM sequencing, and SOLiD sequencing. In April 2017, the European parliament approved the 2012 proposal of European Commission for regulations on in-vitro diagnostic Medical Devices (IVD) and other medical devices. The two new regulations replace the three existing directives on medical devices in order to enhance patient safety. These changes by the EU legislation aids in the development of microbiology diagnostic devices, as they focus on providing transparency of information through EUDAMED (the new European database of medical devices), allowing manufacturers to monitor products, stronger clinical evidence, post-market surveillance, and enhance safety improvements. In February 2019, Biomerieux, biotechnology company specialized in in vitro diagnostics, acquired Invisible Sentinel, a US-based company, for $75 million. This acquisition enables bioMérieux’s to expand its customer segments, innovative alternatives to deliver accurate results by rare pathogen testing and challenging food matrices. Invisible Sentinel provides microbial detection tools and devices for food and beverage molecular testing in order to improve safety, quality and productivity. These provide bioMérieux’s molecular food testing solution, 'GENE-UP®', an opportunity to adapt Invisible Sentinel assays to process high volumes of samples. Major players in the microbiology diagnostics devices and equipment market are Becton Dickinnson and Company, Biomerieux, Danaher, Thermo Fisher Scientific, Abbott Laboratories, Bio-Rad Laboratories Inc., Bruker Corporation, Neogen Corporation, Merck KGaA, Charles River Laboratories International Inc, Don Whitley Scientific Limited, Quidel Corporation, Rapid Micro Biosystems Inc, Sartorius Group, 3M Company, TSI Inc, Vivione Biosciences, LLC, Hologic Inc., F. Hoffmann-La Roche AG, and Sartorius Group. The regions covered in the microbiology diagnostics devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the microbiology diagnostics devices and equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global microbiology diagnostic devices and equipment market is segmented - 1) By Type: Laboratory Instruments, Microbiology Analysers 2) By End User: Hospitals, Diagnostic Centres, Customer Lab Service Providers, Academic Institutes, Research Institutes 3) By Laboratory Instruments: Incubators, Gram Stainers, Bacterial Colony Counters, Petri Dish Fillers, Automated Culture Systems 4) By Micro-Biology Analyzers: Microbiology Diagnostics Instruments, Microscopes 5) By Reagents: Pathogen-Specific Kits, General Reagents

The patient monitoring devices market consists of the sales of patient monitoring devices and related services by entities (organizations, sole traders and partnerships) that manufacture patient monitoring devices used for monitoring vital health parameters. This industry includes establishments that manufacture fetal and neonatal monitoring devices used to monitor heart rates in neonates and pregnant mothers, body weight and temperature monitoring devices, vital parameter monitoring devices used during surgeries, and remote patient monitoring devices.

Medical Devices Market Definition

The medical devices market consists of sales of medical equipment or devices and related services by entities (organizations, sole traders and partnerships) that manufacture medical equipment or devices which are used in the diagnosis, treatment and monitoring of medical conditions. The medical device industry includes establishments that manufacture medical equipment or devices such as in-vitro diagnostic devices, diagnostic imaging equipment, dental equipment and supplies, ophthalmic devices, cardiovascular devices, hospital supplies and other medical devices. The market by value in this report is defined as the revenues that enterprises gain from goods and/or services within the specified market and geography. It does not include revenues from intersegment sales and resales, either further along the supply chain or as part of other products. Only goods and services traded between entities or sold to end consumers are included. Whether specifically stated or not, the markets for goods include related services and the markets for services include related goods.

The weight monitoring and body temperature monitoring devices and equipment market consists of sales of weight monitoring and body temperature monitoring devices and related services. Weight monitoring and body temperature monitoring devices and equipment are the most widely used patient monitoring devices. The global weight monitoring and body temperature monitoring devices and equipment market is expected to grow from $2.94 billion in 2020 to $3.03 billion in 2021 at a compound annual growth rate (CAGR) of 3.1%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $3.84 billion in 2025 at a CAGR of 6.1%. The rising prevalence of obesity is one of the major drivers of the weight monitoring devices and equipment market. According to the World Health Organization (WHO), 1.9 billion adults around the globe were diagnosed, overweight, and also over 340 million children of 5 to 19 years across the globe were overweight. To curb the increase of obesity, weight monitoring devices can play a vital role by reminding the user to follow a certain diet or monitor the exercising habits of the individual. This drives the demand for weight monitoring devices, thus driving the market growth. Product recalls acts as a restraint on the weight monitoring and body temperature monitoring devices and equipment market. For instance, the US Food and Drug Administration (FDA) has recalled many digital thermometers due to wrong calibration and incorrect display of body temperature. Also, thermometers manufactured by 3M company were recalled by the FDA after a prolonged investigation due to incorrect display of body temperature. Similarly, In 2020, the FDA has recalled a specific model electric thermometer manufactured by Cardinal Health, a multinational health care services company. Such a high number of product recall hampers market growth. The use of wearables is a trend that is prevalent in the weight monitoring and body temperature monitoring devices and equipment market. Many companies such as Apple, Google, and Samsung are investing in the research and development of wearables. The wearables have high-end sensors attached to them, which measures and monitors body temperature and weight. Various new products are launched in the wearable category. For example, Blue Spark's, Temp Traq is a wearable temperature monitor. Also, Fitbit wearable tracks and monitor weight. Stringent FDA regulations need to be followed in the weight monitoring and body temperature monitoring devices and equipment market. FDA has a set of good manufacturing practices designed for the monitoring of body temperature and weight monitoring devices. FDA monitors the safety and effectiveness of these devices. Part 880 of the FDA regulations pertain to the general hospital and personal use devices; subpart C relates to personal use monitoring devices. Weight monitoring devices are classified by the FDA as Class I devices. The manufacturers are tasked with the thorough inspection, measuring and testing efficiency, and ensuring it meets the intended purposes. Once this is finished the manufacturer must calibrate the device according to a set of rules or limits to improve the precision and accuracy of the readings. After all, this is completed the FDA will take their final call regarding the certification of the device. Major players in the market are Philips Healthcare, Medtronic, GE Healthcare, Abbott Laboratories, and 3M. The countries covered in the global weight monitoring and body temperature monitoring devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global weight monitoring and body temperature monitoring devices and equipment market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global weight monitoring and body temperature monitoring devices and equipment market is segmented - 1) By Type: Weight Monitoring Devices, Temperature Monitoring Devices 2) By End User: Hospitals & Clinics, Home Settings, Ambulatory Surgical Centers 3) By Temperature Monitoring Devices: Table Top Temperature Monitoring Devices, Hand Held Temperature Monitoring Devices, Wearable Continuous Monitoring Thermometers, Temperature Monitoring Sensors & Smart Temperature Patches

The robotic surgery devices market consists of sales of robotic systems, instruments and accessories and services related to the robotic surgery devices market. Robotic surgery devices are advanced surgical devices compared to traditional laparoscopic surgery devices. These devices are used for Minimally Invasive (MI) surgeries in the eye, brain, heart and other parts of the body. These robotic surgery devices can be applied in Gynecological, Neuro, Orthopedic, and general surgeries. The robotic surgery devices are more cost-effective and introduced to reduce complications, pain, reoperations, etc. The global robotic surgery devices market is expected grow from $4.84 billion in 2020 to $5.13 billion in 2021 at a compound annual growth rate (CAGR) of 6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $9.65 billion in 2025 at a CAGR of 17%. The robotic surgery devices market covered in this report is segmented by product and service into robotic systems, instruments & accessories, services and by surgery type into urological surgery, gynecological surgery, orthopedic surgery, neurosurgery, other applications. The rise in demand for minimally invasive technology is driving the robotic surgery devices market. Minimally Invasive (MI) surgery devices are equipped with imaging and catheter technologies that can be easily inserted into any parts of the body. Robotic surgery procedures are usually associated with minimally invasive surgeries. These technologies are mainly used for heart, laparoscopy, orthopedic, gynecological, and urological surgeries. Robotic surgeries were introduced to reduce patient hospital length of stay (LOS), pain, complications, return to work time, and reoperations. According to the Intuitive Surgical company report, there is a 24% growth year on year for instruments and accessories. For robotic systems, the company has gained 16% growth and overall robotic surgery devices market is growing at a rate of 13% -16%. The Intuitive Surgical company estimates that more than 1.2 million surgical procedures were done by using their robotic systems. Consumer preferences are changing and hospitals are adopting robotic surgery devices to create more value and cost-effective surgical procedures. Expensive robotic surgery is hampering the robotic surgery devices market. Robotic surgery is comparatively more expensive than other traditional ways of surgeries as it is associated with a lot of complications, requires highly trained senior doctors to operate robotic systems/instruments, complex technical operation, and maintenance. A single robotic system costs around $2 million and the surgery costs about a range of $3000 - $6000. The annual maintenance cost of robotic surgery devices usually costs between $100,000 - $170,000. The largest robotic surgery device manufacturer Intuitive Surgical supplies the single-use or disposable surgical tools used for robotic arms for surgeries. This is one of the reasons that robotic surgeries are more costly. The huge cost associated with robotic surgeries is therefore hindering the market growth. The advances in surgical products and technologies in the health care industry are creating more opportunities in the robotic surgery devices market. Increasing investments in R&D is helping investors to create value for the customers by producing medical-surgical products like robotic surgery devices by using the latest technologies. With the use of robotic systems that are equipped with optical imaging, surgical tools, instruments, and accessories, the surgeries are made easier. Some of the surgical advances that are creating more value and opportunity in the healthcare industry include 3-D high definition endoscope (Multi-Angle Rear-Viewing Endoscopic tool) devices for brain surgery, smart surgical glasses (equipped with a video camera and Head-mounted monitor) that act as computers and can used for live observation of surgeries, surgical robots with artificial intelligence that acts as doctors, and humanoid robots which are used for highly critical surgeries in eye and brain. The other advanced surgical tool is remote robotics, which is used to assist with surgery from any remote location. Therefore, the robotic surgery devices are playing an important role in the healthcare industry with their technological advancements and innovations. In July 2019, Intuitive Surgical Inc., an American corporation that develops, manufactures, and markets robotic products, acquired Schölly Fiberoptic’s robotic endoscope business. Schölly Fiberoptic is a major player in the visualization systems for Minimally Invasive (MI) diagnostic and surgical applications. This acquisition integrated Schölly’s robotic endoscope manufacturing line, and two Schölly sites into some of the Intuitive operations which are the robotic-related manufacturing line from Denzlingen (Germany), the manufacturing site in Biebertal (Germany) and the repair site in Worcester, Mass (USA). The acquisition's main aim is to strengthen the Intuitive’s supply chain and increase its manufacturing capacity for visualization products to advance healthcare. The major players covered in the global robotic surgery devices market are Intuitive Surgical, Stryker, Medtronic, Smith & Nephew, TransEnterix, Mazor Robotics, Medrobotics, Accuray, THINK Surgical, TINAVI Medical Technology Co. Ltd., Hansen Medical, Auris Surgical Robotics Inc (Hansen Medical Inc), CMR Surgical, Zimmer Biomet, MedTech, Corindus Vascular Robotics, Renishaw, Verb Surgical, Meere Company, Titan Medical, Stereotaxis, Inc., KUKA AG, Microbot Medical, OMNIlife science Inc., Preceyes BV, Microsure, AvateraMedical GmbH, Medicaroid Corporation, TINAVI Medical Technology Co. Ltd., AOT AG, Robocath, Rob Surgical Systems, Siasun Robot & Automation Co. Ltd., Curexo, Hocoma, Omnicell, Arxium, Ekso Bionics Holdings, Globus Medical, Maxar Technologies Limited. The countries covered in the global robotic surgery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global robotic surgery devices market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global robotic surgery devices market is segmented - 1) By Product and Service: Robotic Systems, Instruments & Accessories, Services 2) By Surgery Type: Urological Surgery, Gynecological Surgery, Orthopedic Surgery, Neurosurgery, Others 3) By End User: Hospitals, Ambulatory Surgery Centers

The lancing devices and equipment market consists of sales of lancing devices and equipment and related services. These devices are used to prick the skin to obtain blood samples for testing glucose levels. The global lancing devices and equipment market is expected to grow from $0.31 billion in 2020 to $0.42 billion in 2021 at a compound annual growth rate (CAGR) of 35.5%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $0.51 billion in 2025 at a CAGR of 5%. Rising prevalence of diabetes is driving the market for lancing devices and equipment as more people depend on lancing devices to test blood glucose levels. Lancing devices are used by diabetics to obtain samples of blood for testing glucose levels in it. According to the International Diabetes Federation, in 2019, around 463 million adults had diabetes and the number is expected to reach 700 million by 2045. This growth in the number of diabetic patients is expected to increase the demand for lancing devices and equipment, thereby driving market growth. Recalls of defective lancing devices is acting as a restraint on the lancing devices and equipment market. A product recall is done by the manufacturer or regulatory body as a precautionary measure when safety issues or defects are discovered that can endanger the consumer. Lancing devices and equipment penetrate the skin and come in direct contact with blood inside the body. Any defect in the product can infect the blood causing risk to the patient's life. For instance, the ACCU-CHECK FastClix Lancing Device by Roche Diagnostics Operations Inc. was recalled by the Food and Drug Administration (FDA) as the needle of the lancet utilized in a finger stick may not completely retract back into the lancet drum as it was intended to. Such recalls discourage product use and affect growth of the market. Lancing device manufacturers are increasingly using custom vacuum technology in lancing devices to minimize pain from poking. Lancing devices that use this technology create a shallow puncture on the skin without hitting the deeper pain nerves and blood is pulled up by vacuum. For example, the Genteel Lancing device is a vacuum blood drawing lancing device which draws blood from the capillaries and can be used on different sites on the body apart from fingers. Lancing devices and equipment manufacturers are governed by regulatory bodies such as the Food and Drug Administration Act (FDA) in the USA. For instance, in the USA, Section 510(k) of the Food, Drug and Cosmetic Act requires manufacturers of lancing devices to register their device with the FDA and notify their intent to market the device at least 90 days before the actual marketing of the device. This period of 90 days allows FDA to classify the device among three prescribed classes (Class I, II or III). The FDA also laid down regulations regarding the application of section 510(K) in case of advancements, or changes made to the lancing device. In October 2018, investment firm Platinum equity acquired Lifescan for $2.1 billion. Lifescan is headquartered in Switzerland and was incorporated in 1887. Lifescan develops and manufactures products for people with diabetes which include lancets, blood glucose meters, testing strips and others. The company serves approximately 20 million patients in more than 90 countries. Major players in the market are Abbott laboratories, B. Braun Melsungen AG, Terumo Corporation, F. Hoffmann-La Roche AG and LifeScan. The countries covered in the global lancing devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global lancing devices and equipment market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global lancing devices and equipment market is segmented - 1) By Product: Safety Lancets, Standard Lancets 2) By Type: Reusable, Disposable 3) By End User: Hospitals and Clinics, Homecare and Home Diagnostics, Diagnostic Centres and Medical Institutions, Research and Academic Laboratories, Others 4) By Penetration Depth: 0.8mm-1mm, 1.1mm- 1.5mm, 1.6mm-2.0mm, Others

The Polymerase Chain Reactions (PCR) devices and reagents market consists of sales of PCR devices and reagents and related services. The services includes only installation and maintenance services offered by equipment manufacturers. Polymerase Chain Reactions (PCR) devices are designed to aid scientist in producing multiple copies of specific DNA segments. The global polymerase chain reactions (PCR) devices, reagents and uses market was valued at about $3.86 billion in 2018 and is expected to grow to $5.09 billion at a CAGR of 7.2% through 2022. Growing prevalence of infectious diseases across the world is driving the polymerase chain reactions devices and reagents market. Polymerase chain reactions devices are used in clinical laboratories to detect the presence of infectious disease. In a report published in 2018 by the World Health Organization, it was reported that around 17 million people are killed in a year due to infectious disease. Also, the same report stated that 30 new infectious disease have emerged in the last 20 years. According to the National Centre for Health Statistics, in 2016, 15.5 million people in the US visited a physician, due to an infectious disease. In 2017, there were major outbreaks of infectious disease like hepatitis A outbreak in California, USA and Cholera in Yemen. Such instances are increasing the demand for clinical diagnostic services and thereby driving the polymerase chain reactions devices and reagents market. Emergence of alternatives is a major restraint on the growth of polymerase chain reaction devices and reagents market. In the field of DNA sequencing, polymerase chain reaction technique has competitors like Next Generation Sequencing and Sanger Sequencing which provides similar utility as PCR devices and reagents and even better results in some cases, thus increasing the competition in the market and thereby limiting PCR devices and reagents growth. For instance, in a study conducted in 2016, 138 FFPE non-small lung cancer samples were examined, with assays developed through Sanger, Next Generation Sequencing and polymerase chain reaction techniques. All three assays were compared and it was reported that assays developed by NGS and QPCR exhibited similar analytical sensitivity, simplicity and high level of concordance. Moreover, it was found that NGS assays proved to be better than qPCR in displaying more accurate information about allele sequence, mutation frequency and in detection of non-hotspot mutations. This emergence of alternative procedures is expected to restrain the growth of the market during the forecast period. Companies in the polymerase chain reaction devices and reagents market are increasingly focusing on Digital PCR due to its higher accuracy compared to conventional PCR. Conventional PCR is an end-point investigation which is not fully quantified because the enhanced item is distinguished by agarose gel electrophoresis. Digital PCR expands on customary PCR enhancement and fluorescent-probe– based identification techniques to give comprehensive evaluation of nucleic acids without the requirement for standard bends. The companies investing in digital polymerase chain reaction technology includes BioRad Technologies, Atlas Genetics, OriGene Technologies STST-Diagnostica, Ugen Tec and Genesis Healthcare Company. Major players in the Polymerase Chain Reactions (PCR) devices and reagents market are Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Becton, Dickinson and Company and Abbott.